Vaccine adverse reactions, revisiting mRNA trial data
June 16, 2026
17 min
Full
170 of 364
June 16, 2026
Vaccine adverse reactions, revisiting mRNA trial data
0:00 / 17:23
Excerpt playback isn’t available for this episode — use the full-episode link.
Search the Record
Moment search isn’t open for this episode yet
When it opens, you’ll be able to type any phrase and jump straight to the second it was said.
Dr John Campbell Episodes Around June 16, 2026
Episode 170 of 364 — walk the feed in the order it was published.
17:23This episodeVaccine adverse reactions, revisiting mRNA trial data
Summary
Swine flu vaccine (1976), 1 serious event per 100,000 vaccinees, Vaccine withdrawn
Rotavirus vaccine Rotashield, (1999),1 to 2 serious events per 10,000 vaccinees, Vaccine withdrawn
Covid mRNA vaccines, 1 serious event per 800 vaccinees, Vaccine officially promoted
Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults
https://pubmed.ncbi.nlm.nih.gov/36055877/
Free full text available
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428332/
Why We Question the Safety Profile of mRNA COVID-19 Vaccines
(Robert M Kaplan and Sander Greenland)
https://sensiblemed.substack.com/p/why-we-question-the-safety-of-covid
Using publicly available data from Pfizer and Moderna studies,
we found one serious adverse event for each 800 vaccinees.
That translates to about 1,250 serious events for each million vaccine recipients.
US, Spain, Australia
Study to evaluate serious adverse events of special interest observed in mRNA COVID-19 vaccine trials.
Secondary analysis of serious adverse events reported in the placebo-controlled, phase III randomized clinical trials,
of Pfizer and Moderna mRNA COVID-19 vaccines
Results
Pfizer and Moderna mRNA COVID-19 vaccines were associated with an excess risk of serious adverse events of special interest
Pfizer
10.1 per 10,000 vaccinated over placebo baselines of 17.6
Moderna
15.1 per 10,000 vaccinated over placebo baseline of 42.2
Combined, the mRNA vaccines
Associated with an excess risk of serious adverse events of special interest of 12.5 per 10,000 vaccinated
Pfizer trial
Pfizer vaccine group
52 serious AESI (27.7 per 10,000) were reported
Pfizer placebo group
33 serious AESI (17.6 per 10,000) were reported
36 % higher risk of serious adverse events in the vaccine group
Risk difference 18.0 per 10,000 vaccinated
Moderna trial
Moderna trial, vaccine group
87 serious AESI (57.3 per 10,000) were reported
Moderna trial, placebo group
64 serious AESI (42.2 per 10,000) were reported
6 % higher risk of serious adverse events in the vaccine group
Risk difference 7.1 per 10,000 vaccinated
Discussion
The excess risk of serious adverse events found in our study points to the need for formal harm-benefit analyses,
particularly those that are stratified according to risk of serious COVID-19 outcomes.